SLC5A2 and type 2 diabetes mellitus: In a study by Varshney et al., the risk of urinary and genital infections was compared between SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists in elderly patients (65 and older) with type 2 diabetes.